EW Seeks Mitral Leadership: Sapien M3 Early Real-World Data Support Replacement

研报英文原文证据摘录

EW Seeks Mitral Leadership: Sapien M3 Early Real-World Data Support Replacement

TD Cowen Edwards Lifesciences Corp.

Global Research May 21, 2026

Strong Technical Success Despite Early Commercial Learning Curve

The most important procedural finding is that the Sapien M3 delivery appears feasible across

a relatively broad early European center base. Technical success was 98.1%, mean procedure

time was 150 minutes, pericardial effusion occurred in 2%, and urgent surgery was required in

1% of patients.

That is an important signal given the procedural complexity of Sapien M3, which requires a

docking system followed by valve implantation through a transseptal approach. This is not

yet a streamlined TEER-like workflow, and all cases were still proctored, but the early safety

and technical performance suggest the platform can move beyond a small group of super-

specialized trial operators.

Symptom Relief and Early Remodeling: Clinical Benefit Emerging Quickly

At baseline, 77.7% of patients were NYHA class III/IV; by 30 days, only approximately 20%

remained class III/IV. Early reverse remodeling was also evident, with reductions in LV end-

diastolic and LV end-systolic dimensions, alongside an expected small decline in left ventricular

ejection fraction (LVEF). This is consistent with effective MR elimination: once regurgitant

volume is eliminated, measured LVEF can fall modestly because the ventricle is no longer

ejecting into a low-pressure left atrial circuit. Whether LV volumes, functional status, heart

failure hospitalizations, and survival improve over longer follow-up will be crucial in the

evaluation of the clinical effectiveness of the Sapien M3 platform.

Safety Profile: Encouraging Mortality, but Thrombosis and Hemolysis Will Be Monitored